Trial reportArthritis research & therapy2018
Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab.
Trial report in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Imaging methods in polymyalgia rheumatica: a systematic review.Rheumatology international · 2023Pooled it
- Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Concordance and agreement between different activity scores in polymyalgia rheumatica.RMD open · 2024Trial
- Trial
- Integration of Clinical, Cytokine, and Ultrasound Data Using Machine Learning Reveals a Multidimensional Inflammatory Signature in Polymyalgia Rheumatica.Journal of personalized medicine · 2026Article
- Choroidal thickness as a biomarker of inflammatory activity in patients with polymyalgia rheumatica receiving anti-IL-6 treatment.Frontiers in medicine · 2026Article
- Modern Management of Isolated Polymyalgia Rheumatica.Rheumatology and therapy · 2025Review
- Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.BMC rheumatology · 2024Article
- Magnetic resonance imaging in polymyalgia rheumatica-contrast enhancement is not always needed.Zeitschrift fur Rheumatologie · 2024Article
- Polymyalgia rheumatica: An update (Review).Experimental and therapeutic medicine · 2023Article
- Disease stratification in GCA and PMR: state of the art and future perspectives.Nature reviews. Rheumatology · 2023Review
- Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?Frontiers in immunology · 2023Review
- Article
- Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica.Annals of the rheumatic diseases · 2022Article
- Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?Cureus · 2022Review
- Differential Diagnosis of Inflammatory Arthritis from Musculoskeletal Ultrasound View.Rheumatology and immunology research · 2022Review
- Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for polymyalgia rheumatica.Rheumatology (Oxford, England) · 2022Article
- Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study.Journal of clinical medicine · 2021Article
- Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.Nature reviews. Rheumatology · 2020Review
- Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica.Rheumatology international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed inflammatory changes using ultrasound (US) and magnetic resonance imaging (MRI) in patients taking tocilizumab for polymyalgia rheumatica (PMR).
methodsEighteen patients were included in the prospective open-label TENOR study and received three tocilizumab infusions, without corticosteroids. B-mode and power Doppler US and MRI (T1 and T2-short time inversion recuperation weighted sequences) of the hips and shoulders were performed at weeks 0, 2, and 12. Subacromial, trochanteric, and iliopsoas bursitis and intraarticular glenohumeral and coxofemoral effusions/synovitis were scored from 0 to 3. Changes over time and US-MRI correlations were evaluated.
resultsAt baseline, the proportions of shoulders and hips with bursitis were 93 and 100% by MRI and 61 and 13% by US; and the corresponding proportions for intraarticular effusions/synovitis were 100 and 100% by MRI and 57 and 53% by US. Imaging findings did not improve during the first two treatment weeks. From baseline to week 12, bursitis improved significantly at all four joints by MRI (P = 0.005) and US (P = 0.029) and intraarticular effusions/synovitis by US only (P = 0.001). The proportion of abnormalities that improved by week 12 was 42% by MRI and 37% by US. MRI detected bursitis in a larger proportion of hips (73% versus 13%) and US in a larger proportion of shoulders (57% versus 28%), whereas no difference was found for intraarticular effusions/synovitis. At baseline, agreement between US and MRI findings was poor.
conclusionsUS and MRI showed significant improvements in inflammatory lesions during tocilizumab treatment of PMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.